Discussion
Enrollment of the first group of participants in a Phase 3 clinical trial testing obudanersen in people with Angelman syndrome is complete, with 136 children taking part in the study to determine whether the treatment can improve communication. The REVEAL study (NCT06914609) will evaluate the therapy in kids and adults.